# Study of Chemoimmunotherapy for High-Risk Neuroblastoma

> **NCT03189706** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Neuroblastoma (NB)

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** temozolomide
- **BIOLOGICAL:** Hu3F8
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT03189706
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-12
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189706, "Study of Chemoimmunotherapy for High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03189706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*